- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Advocates Demand Oral Parity in North Carolina
The demand for oral parity for oncology medications is back up for vote in the Senate in North Carolina.
Patient advocacy groups in North Carolina, like ACSCAN, are demanding that the state should implement the oral/infusion cancer drug parity law. While Oregon was the first state to pass the law in 2008, 39 states and the District of Columbia have followed suit. Today, North Carolina is one of 11 states where insurers demand higher out-of-pocket costs from patients on oral anticancer agents, compared with those who get infusions or injections.
“It should not matter what method of chemotherapy a cancer patient is receiving, whether it’s an IV infusion or a pill,” said Christine Weason, the North Carolina government relations director for the American Cancer Society Cancer Action Network in an interview. “It’s just about fairness.” A bill to this effect, passed in the North Carolina House in April this year, is currently pending in the Senate.
Read more in The Charlotte Observer.
Watch a panel discussion among payers and healthcare policy experts on the topic that was recently convened by AJMC.
Read more here: http://www.charlotteobserver.com/living/health-family/article27365617.html#storylink=cpy
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
